Altimmune, Inc. (ALT) vs Cerus Corporation (CERS)
A side-by-side comparison of Altimmune, Inc. and Cerus Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ALT
Altimmune, Inc.
$2.66HealthcareDelayed quote: Oct 6, 2026, 12:45 PM EDT
CERS
Cerus Corporation
$2.36HealthcareDelayed quote: Oct 6, 2026, 12:45 PM EDT
Total return — ALT vs CERS
growth of $100 · dividends reinvested · last 9yALT -98.0% (-35.2%/yr)CERS +15.8% (+1.6%/yr)CERS compounded faster over this window
Log scale — wide-divergence pair
ALT CERS
ALT vs CERS: by the numbers
- •ALT is the larger company ($517M vs $476M market cap).
- •Both run net losses; CERS's is the smaller (-3.06% vs -296000.00% net margin).
- •CERS grew revenue faster over the past five years (15.74% vs -65.38% CAGR).
Metrics side by side
Valuation
| Metric | ALT | CERS |
|---|---|---|
| P/S ratio | 16687.12 | 2.15 |
| P/B ratio | 1.09 | 6.79 |
| EV / EBITDA | N/A | 8097.24 |
Profitability
| Metric | ALT | CERS |
|---|---|---|
| Gross margin | 100.00% | 52.05% |
| Operating margin | -230460.98% | -0.73% |
| Net margin | -296000.00% | -3.06% |
| ROE | -19.35% | -9.69% |
| ROIC | -19.47% | -1.08% |
Growth (annualized)
| Metric | ALT | CERS |
|---|---|---|
| Revenue CAGR (5Y) | -65.38% | 15.74% |
| Total return CAGR (5Y) | -25.30% | -17.30% |
Frequently asked
- Which has grown faster, ALT or CERS?
- Over the past five years, CERS grew revenue faster — ALT at a -65.38% CAGR versus CERS at 15.74%.
- How have ALT and CERS total returns compared?
- Over the past 5 years, ALT delivered -25.30% and CERS delivered -17.30% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Altimmune ROECerus ROEAltimmune operating marginCerus operating marginAltimmune revenue growthCerus revenue growthAltimmune free cash flowCerus free cash flow
Altimmune & Cerus appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.